Price
No data yet.
Social Signal Score
Revenue
$0.00Company Profile
- CEO
- Paul Y. Song
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 26
- Beta
- 0.72
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -15.78
Financials
Revenue
$0.00-100.0%Net Income
$15.35MEBITDA
$16.24MFree Cash Flow
$-2.85MEPS (diluted)
$-0.04Shares Outstanding (diluted)
28.83M+34.4%Operating Expenses
$4.67MCash & Debt
$6.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2024 | $0.00 | $-44.29M | $-1.54 |
| 2023 | $0.00 | $-82.95M | $-5.38 |
| 2022 | $77.0K | $-26.75M | $-1.25 |
| 2021 | $426.0K | $-23.27M | $-1.08 |
Valuation
NKGNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·6h ago·Neutral
…oculeucel for Neurodegenerative Diseases at 4th Great Bay Cell and Gene Therapy Forum SANTA ANA, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the Company's lead investigatio…
View source ↗ - Newsglobenewswire.com·5d ago·Neutral
…al of Troculeucel in Neurodegenerative Diseases at Biologics Manufacturing Korea 2026 SANTA ANA, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the potential of troculeucel, t…
View source ↗
Insider trading
Open-market buys and sells by NKGN officers and directors.
- Bought
- $15.5m
- Sold
- —
10 trades
0 trades
- Cfic-2015 Nv Family Investments, Llcbought
- Cfic-2015 Nv Family Investments, Llcbought
- Song Paul Y.bought
- Song Paul Y.bought
- Song Paul Y.bought
- Song Paul Y.bought
- Graf James Abought
- Graf James Abought
37 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NKGN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.